The Democratic Republic of the Congo (DRC) has received an initial allocation of 70,000 doses of the Ervebo Ebola vaccine to support the response to the ongoing Bundibugyo virus disease outbreak.
The World Health Organisation (WHO) and the Africa Centres for Disease Control and Prevention (Africa CDC) disclosed this in a joint statement on Thursday.
The allocation followed a request by the DRC government last week for vaccines from the global Ebola virus disease vaccine stockpile managed by the International Coordinating Group on Vaccine Provision (ICG).
Of the 70,000 doses, 20,000 will be used in a Phase III clinical trial to assess whether Ervebo can protect against Bundibugyo virus, while the remaining 50,000 doses will be administered to frontline and health workers in line with recommendations by the WHO Strategic Advisory Group of Experts on Immunisation (SAGE).
Why the vaccine is being tested
The decision to use part of the allocation in a clinical trial reflects the uncertainty surrounding the effectiveness of Ervebo against Bundibugyo virus.
Ervebo is a licensed vaccine recommended for use during outbreaks caused by the Zaire species of Ebola virus. The current outbreak in the DRC, however, is caused by Bundibugyo virus, a different species of the Ebola virus.
WHO said it is not yet known whether Ervebo can protect humans against Bundibugyo virus, although early laboratory and animal studies suggest that it may provide some protection.
The Phase III trial is therefore expected to generate evidence on whether the vaccine can offer protection against the virus and help guide future decisions on its use during similar outbreaks.
WHO said people offered the vaccine, whether as part of the trial or outside it, must be informed about the potential risks, benefits and limitations of using Ervebo against Bundibugyo virus and must provide informed consent.
Outbreak spread
According to the latest WHO disease outbreak update, 4,665 confirmed cases and 2,184 deaths had been reported as of 12 August.
The outbreak has expanded from the Mongbwalu health zone in Ituri Province to 54 health zones across six provinces: Ituri, North Kivu, South Kivu, Haut-Uélé, Tshopo and Bas-Uélé.
WHO described the outbreak as being in a phase of intense transmission and said it was the largest Ebola outbreak ever reported in the DRC.
The outbreak was declared on 15 May and has been driven by factors including population movement, insecurity, artisanal mining activities and cross-border travel involving Uganda and South Sudan.
The scale of the outbreak has consequently increased pressure on health authorities and researchers to deploy available interventions while developing tools specifically suited to the Bundibugyo virus.
Vaccine development
In July, PREMIUM TIMES reportedthat the first human clinical trial of an experimental Bundibugyo Ebola vaccine had begun at the University of Oxford.
The Phase I trial, known as BD-Ebov, is assessing the safety of the experimental ChAdOx1 BDBV vaccine and its ability to stimulate immune responses in healthy adults.
The vaccine was developed by the University of Oxford’s Oxford Vaccine Group and Pandemic Sciences Institute in collaboration with the Serum Institute of India and the Coalition for Epidemic Preparedness Innovations (CEPI).
Unlike Ervebo, which is licensed for use against Zaire ebolavirus, ChAdOx1 BDBV was specifically designed to target Bundibugyo virus.
The development of a vaccine specifically targeting the virus is considered important because there is currently no approved vaccine specifically for Bundibugyo virus.
The use of Ervebo in the current outbreak could therefore serve a dual purpose; providing protection to health workers who are at high risk of exposure while generating evidence on whether an existing Ebola vaccine can provide protection against another species of the virus.
WHO’s technical advisory group on candidate vaccine prioritisation recently recommendedthat Ervebo be included in a randomised clinical trial during the ongoing DRC outbreak following a review of emerging evidence on its potential cross-protection against Bundibugyo virus.
Community response
Beyond the vaccines, WHO and Africa CDC said the success of the response would also depend on the involvement of communities affected by the outbreak.
The two organisations welcomed the allocation of the vaccines and supported the DRC’s focus on a community-led approach, which they said would give communities a central role in the response.
Such an approach, they said, would help protect affected populations, save lives and contain transmission while ensuring that people receiving the vaccine understand its potential benefits and limitations.
The ICG partners are WHO, the International Federation of Red Cross and Red Crescent Societies, Médecins Sans Frontières (MSF) and United Nations Children’s Fund (UNICEF), while Gavi, the Vaccine Alliance, provides funding for the global vaccine stockpile.
WHO and Africa CDC said they remained committed to supporting the DRC government to end the outbreak while generating scientific evidence that could strengthen preparedness for future outbreaks.
The continued spread of the virus has also raised concerns beyond the DRC because of the potential for cross-border transmission.
Nigeria has subsequently heightenedits preparedness, with the Nigeria Centre for Disease Control and Prevention (NCDC) activating its Emergency Operations Centre, strengthening surveillance at points of entry and increasing monitoring across states.
The federal government also identified21 states and the Federal Capital Territory as being at high risk of Ebola infection following a dynamic risk assessment.
State governments were urged to strengthen surveillance, isolation capacity and infection prevention and control measures.
Discover more from Premium Times Nigeria
Subscribe to get the latest posts sent to your email.
Médecins Sans Frontières (MSF) has warned that shortages of a lifesaving medicine are forcing medical teams to ration treatment for diphtheria patients in northern Nigeria, where more than 28,000 confirmed infections and 1,100 deaths have been reported this year.
The warning comes as figures attributed to the Nigeria Centre for Disease Control and Prevention (NCDC) show that the outbreak continues to spread, particularly among children who are unvaccinated or have not received all their recommended vaccine doses.
In a statement issued on Friday, MSF said supplies of diphtheria antitoxin (DAT), which neutralises the toxin responsible for potentially fatal complications, were dangerously low.
The organisation called on federal and state authorities, donors and international partners to urgently secure additional medicines and vaccines, ensure their timely clearance at ports and improve distribution to affected communities.
Treatment shortage threatens patients
MSF’s Medical Coordinator in Nigeria, David Kizito, warned that the shortage could compromise the treatment of severely ill patients.
“Our stocks are dangerously low, and we risk being unable to treat children and save lives as the outbreak continues,” he said.
MSF photograph of a healthcare worker examining a diphtheria patient at the Infectious Disease Hospital in Amanawa, Sokoto, on 8 October 2026
Diphtheria is a vaccine-preventable bacterial infection that can cause fever, sore throat and a thick membrane in the throat, sometimes obstructing breathing. Severe infections can damage the heart, nerves and kidneys.
According to the World Health Organisation (WHO), diphtheria antitoxin neutralises toxins circulating in the bloodstream, while antibiotics help eliminate the bacteria and reduce transmission.
Early administration of antitoxin is particularly important because it cannot reverse damage once the toxin has entered body cells.
MSF said limited global production and inconsistent availability had left treatment facilities struggling to obtain adequate supplies.
However, the organisation did not specify which facilities had exhausted their stocks, how many patients had been unable to obtain treatment or whether any deaths were directly attributable to the shortages.
Nigeria records 1,126 deaths
The warning comes amid a prolonged outbreak that began in late 2022.
PREMIUM TIMES reports that a situation report issued on 11 November by the International Federation of Red Cross and Red Crescent Societies(IFRC) and the Nigerian Red Cross Society, citing NCDC data, indicates that Nigeria recorded 37,529 suspected diphtheria cases, 28,151 confirmed infections and 1,126 deaths in 2026 as of 7 November.
The report said the outbreak had affected 26 states and the Federal Capital Territory, covering 361 local government areas.
Kano accounted for 12,008 confirmed cases, approximately 43 per cent of the national total.
The figures are substantially higher than those in MSF’s latest statement, which relied on NCDC statistics from 9 August, when 406 deaths had been reported for 2026.
The difference reflects reporting from separate periods and may include subsequent updates to surveillance records.
Katsina: 70 severe cases in 18 days
In Katsina State, MSF reported managing 86 diphtheria cases between 26 October and 12 November, including 70 classified as severe and 16 as non-severe.
Severe infections accounted for approximately 81 per cent of the patients managed by its teams during the period, although the figures do not represent the severity of all diphtheria infections recorded across the state.
MSF said its teams also reached 1,315 contacts through surveillance and contact-tracing activities. Of these, 1,301 received vaccinations, while 1,311 were given preventive antibiotics.
The organisation did not provide the locations of the cases or a breakdown of recoveries and deaths.
The development follows earlier concerns about the capacity of health facilities to manage the outbreak.
On 31 August, PREMIUM TIMES reported that the Federal Teaching Hospital (FTH), Katsina, was struggling with an influx of suspected and confirmed diphtheria patients, leaving its children’s ward under considerable pressure.
The hospital attributed the overcrowding partly to referrals from other facilities across the state.
In response, the federal government announced an emergency multi-agency task force to strengthen surveillance, immunisation and access to treatment in Katsina and Kano.
The intervention included plans to supply additional antitoxin, antibiotics, medical personnel and protective equipment to FTH Katsina.
Authorities also announced plans to establish treatment annexes across Katsina’s three senatorial districts — Katsina, Daura and Funtua — to reduce pressure on the referral hospital.
MSF’s latest statement did not indicate whether those facilities had become operational or how much additional antitoxin had been delivered since the intervention was announced.
Zamfara vaccine shortage
In neighbouring Zamfara State, MSF said its supported facilities in Gusau recorded more than 671 diphtheria admissions over approximately one month beginning on 6 October.
Most patients were children, while four out of every five had not been vaccinated.
The organisation also reported a substantial shortfall in vaccine supplies for an emergency immunisation campaign.
Of the 90,000 doses required, only 25,000 had been supplied, representing approximately 28 per cent of the stated requirement.
MSF said it was working with government health authorities to secure the outstanding doses and expand vaccination activities.
The shortfall highlights the continuing difficulties facing efforts to protect children against the disease.
In October, PREMIUM TIMES reportedthat the Executive Director of the National Primary Health Care Development Agency (NPHCDA), Muyi Aina, said about 93 per cent of children affected by recent diphtheria outbreaks had not received their full recommended vaccine doses.
Mr Aina said some had never been vaccinated, while others had received fewer than the three recommended doses. He identified misinformation and vaccine hesitancy among the challenges affecting immunisation uptake.
MSF’s response
Despite the challenges, MSF said its teams had treated more than 9,000 diphtheria patients through facility-based and community interventions since the beginning of its 2026 response.
In Kano, the organisation supported vaccination campaigns in April and June, administering more than 835,000 doses to children in partnership with the state Ministry of Health.
It also supported two vaccination rounds in Sokoto between February and April, reaching 49,018 children under 15.
The organisation said it was supporting treatment, surveillance, infection prevention and vaccination efforts in several northern states, alongside government health authorities.
MSF called for increased global production of diphtheria antitoxin and sustained investment in routine childhood immunisation to prevent further outbreaks.
The latest warning also draws renewed attention to the emergency measures announced by the federal government in August, particularly the delivery of antitoxin supplies and the proposed expansion of treatment facilities in Katsina.
The extent to which those interventions have improved access to treatment remains to be established.
Discover more from Premium Times Nigeria
Subscribe to get the latest posts sent to your email.
Women in northern Nigeria continue to bear a disproportionate burden of maternal deaths, with the Northwest and Northeast geopolitical zones accounting for about three-quarters of reported fatalities in health facilities, according to the 2026 Joint Annual Review (JAR) Statistical Book.
The report also highlights significant disparities in maternal health outcomes between rural and urban areas, with rural women recording a maternal mortality ratio of 656 deaths per 100,000 live births, compared with 444 deaths per 100,000 live births in urban areas.
Produced by the Federal Ministry of Health and Social Welfare, the report reviews the third year of implementation of the Health Sector Strategic Blueprint. It was presented at the third Nigeria Health Sector Joint Annual Review in Abuja on 10 November.
The findings highlight persistent inequalities in maternal healthcare access and outcomes, despite a reported decline in maternal deaths across health facilities nationally.
According to the report, Nigeria recorded thousands of maternal deaths in health facilities between January and September 2026, although the figures represent only deaths captured by the facility reporting system.
The ministry acknowledged that the figures could be underreported or overreported but described the data as reliable for monitoring trends in the health sector.
Maternal mortality remains high
Maternal mortality refers to the death of a woman during pregnancy, childbirth or within 42 days of the termination of pregnancy from causes related to or aggravated by the pregnancy or its management.
Most maternal deaths are preventable through timely access to quality antenatal care, skilled birth attendance, emergency obstetric services and appropriate postnatal care.
Despite the reported improvements, Nigeria’s maternal mortality ratio remains a major public health concern.
The JAR Statistical Book puts the country’s maternal mortality ratio at 572 deaths per 100,000 live births, significantly above the Sustainable Development Goal (SDG) target of fewer than 70 deaths per 100,000 live births by 2030.
The burden is particularly concerning given Nigeria’s contribution to global maternal deaths.
In its 2023 report, titled “Improving Maternal and Newborn Health and Survival and Reducing Stillbirths: Progress Report 2023”, the World Health Organisation (WHO) estimated that Nigeria recorded 82,000 maternal deaths, 181,000 stillbirths and 277,000 neonatal deaths in 2020.
The combined 540,000 deaths accounted for 12 per cent of global maternal, stillbirth and neonatal deaths, despite Nigeria contributing only six per cent of global live births.
The report ranked Nigeria second after India among countries with the highest combined burden of maternal deaths, stillbirths and neonatal deaths.
Reported maternal deaths decline
The JAR data indicate a downward trend in facility-reported maternal deaths over the review period.
The country recorded 5,391 maternal deaths in health facilities in 2024, compared with 4,455 in 2025.
The figure declined further in 2026, although the exact total requires confirmation against the final statistical table. The quarterly data also indicate improvements.
Following a peak in the second quarter of 2024, maternal deaths and the maternal mortality ratio generally declined. By the third quarter of 2026, the maternal mortality ratio had fallen to 128 deaths per 100,000 live births, representing a reduction of about 46 per cent from the earlier peak.
Maternal deaths during the same period also declined by approximately 40 per cent to 947.
However, these improvements have not been evenly distributed across the country.
Northern states bear the burden
According to the report, maternal deaths over the past three years were heavily concentrated in the Northwest and Northeast geopolitical zones.
By 2026, the two zones together accounted for approximately three-quarters of all documented maternal deaths in health facilities.
The five northern states with the highest maternal mortality burden were Kano, Borno, Jigawa, Yobe and Katsina.
While the national figures showed a downward trend, maternal deaths reportedly increased across the two northern zones, contrasting with reductions recorded in southern parts of the country.
In most southern states, fewer than 50 maternal deaths were reported. The states with the lowest recorded numbers included Osun (four deaths), Abia (five), Enugu (eight), Ekiti (nine), and Bayelsa (nine).
Maternal morbidity
Beyond deaths, the report also highlights the burden of maternal morbidity, including complications that can have lasting effects on women’s health, wellbeing and livelihoods. In 2026, approximately 3,060 women were diagnosed with vesicovaginal fistula (VVF), compared with 4,350 in 2025.
VVF is an abnormal opening between the bladder and vagina that can result in continuous, involuntary leakage of urine, often following prolonged or obstructed labour.
Of the women diagnosed in 2026, 1,737 underwent surgical repair, representing 56.8 per cent of those diagnosed. This was lower than in 2025, when 2,564 women (59 per cent) underwent repairs.
The Northwest and Northeast again recorded the highest burden, with 1,420 and 982 cases, respectively, in 2026. The figures underscore the need to strengthen access to emergency obstetric care, timely referrals and surgical treatment, particularly in underserved communities.
Discover more from Premium Times Nigeria
Subscribe to get the latest posts sent to your email.